Your browser is no longer supported. Please, upgrade your browser.
BIIB Biogen Inc. daily Stock Chart
Biogen Inc.
IndexS&P 500 P/E15.32 EPS (ttm)21.72 Insider Own0.45% Shs Outstand199.80M Perf Week5.63%
Market Cap66.51B Forward P/E11.36 EPS next Y29.29 Insider Trans7.45% Shs Float195.85M Perf Month0.25%
Income4.45B PEG3.13 EPS next Q6.89 Inst Own93.80% Short Float1.45% Perf Quarter4.32%
Sales13.45B P/S4.94 EPS this Y24.50% Inst Trans0.61% Short Ratio2.13 Perf Half Y-2.30%
Book/sh65.26 P/B5.10 EPS next Y2.17% ROA17.60% Target Price385.63 Perf Year12.43%
Cash/sh17.71 P/C18.80 EPS next 5Y4.90% ROE33.40% 52W Range249.17 - 388.67 Perf YTD10.62%
Dividend- P/FCF10.95 EPS past 5Y22.70% ROI23.60% 52W High-14.36% Beta1.10
Dividend %- Quick Ratio2.00 Sales past 5Y14.20% Gross Margin86.50% 52W Low33.59% ATR8.04
Employees7800 Current Ratio2.30 Sales Q/Q6.60% Oper. Margin43.80% RSI (14)55.11 Volatility1.68% 2.40%
OptionableYes Debt/Eq0.46 EPS Q/Q17.00% Profit Margin32.90% Rel Volume1.07 Prev Close324.71
ShortableYes LT Debt/Eq0.46 EarningsJan 29 BMO Payout0.00% Avg Volume1.34M Price332.87
Recom2.00 SMA201.03% SMA504.10% SMA2003.44% Volume1,434,502 Change2.51%
Dec-21-18Initiated BTIG Research Buy
Oct-19-18Downgrade Bernstein Outperform → Mkt Perform
Oct-08-18Reiterated Citigroup Buy $483 → $470
Oct-01-18Resumed Cantor Fitzgerald Overweight $400
Aug-07-18Resumed Stifel Buy $394
Jul-25-18Reiterated SunTrust Buy $321 → $392
Jul-10-18Downgrade Robert W. Baird Outperform → Neutral
Jul-06-18Upgrade Citigroup Neutral → Buy
May-31-18Upgrade Canaccord Genuity Hold → Buy $350 → $335
Apr-25-18Upgrade Robert W. Baird Neutral → Outperform
Apr-05-18Downgrade Barclays Overweight → Equal Weight $395 → $295
Feb-16-18Downgrade Argus Buy → Hold
Feb-05-18Reiterated Mizuho Buy $400 → $433
Jan-26-18Reiterated H.C. Wainwright Buy $340 → $363
Jan-24-18Reiterated Canaccord Genuity Hold $340 → $350
Jan-17-18Reiterated Canaccord Genuity Hold $340 → $350
Dec-22-17Reiterated Nomura Buy $355 → $420
Dec-20-17Upgrade Credit Suisse Neutral → Outperform
Oct-27-17Initiated Canaccord Genuity Hold $340
Oct-25-17Reiterated RBC Capital Mkts Sector Perform $315 → $313
Feb-15-19 04:12PM  Biogen Inc. -- Moody's announces completion of a periodic review of ratings of Biogen Inc. Moody's
10:28AM  Alkermes (ALKS) Q4 Earnings & Revenues Surpass Estimates Zacks
Feb-14-19 06:08PM  Alkermes Plc (ALKS) Q4 2018 Earnings Conference Call Transcript Motley Fool
01:00PM  Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings Zacks
10:08AM  Should You Buy Viking Therapeutics After Gilead Drug Failure? InvestorPlace
Feb-11-19 10:09AM  The Zacks Analyst Blog Highlights: Visa, Charter, Biogen, BP and BB&T Zacks
Feb-09-19 01:12AM  Weekly Top Insider Buys Highlight for the Week of Feb. 8
Feb-08-19 04:16PM  Top Research Reports for Visa, Charter Communications & Biogen Zacks
Feb-07-19 04:35PM  Biogen Sheds $5 Billion of Value as Drug Challenge Vexes Street Bloomberg -7.36%
04:11PM  Why Biogen's 'Battle-Tested' MS Drug Could Win Another Patent Dispute Investor's Business Daily
01:29PM  Biogen Stock Slips on a Setback in a Patent Dispute With Mylan
Feb-06-19 05:45PM  Biogen stock declines as patent office says Mylan patent win likely MarketWatch
Feb-04-19 09:27AM  Alkermes Sinks as FDA Refuses to Approve Depression Drug Zacks
Feb-02-19 01:52PM  Insider Buys Of The Week: Biogen, Discover Financial, Kinder Morgan Benzinga
Feb-01-19 02:11PM  German firm that serves gene therapy biotechs opens Cambridge HQ American City Business Journals
09:48AM  6 Biotech Stocks to Watch Now Motley Fool
06:40AM  How Should You Price Biogen Inc.s (NASDAQ:BIIB) Stock? Simply Wall St.
Jan-31-19 02:45PM  Here are Boston-area biotechs pursuing Parkinson's treatments American City Business Journals
Jan-30-19 11:11PM  Edited Transcript of BIIB earnings conference call or presentation 29-Jan-19 1:00pm GMT Thomson Reuters StreetEvents
04:49PM  Biogen Looks to 2020 Motley Fool
04:42PM  Roche Scraps Alzheimer's Test But Investors Punished This Stock Investor's Business Daily
12:26PM  Stryker Corp's Profit Skyrockets
11:18AM  Ionis Wins Price Target Hike On Partner Biogen's Guidance Benzinga
11:08AM  Biotech Giants Amgen and Biogen Fall on Earnings, Alzheimers News
Jan-29-19 04:21PM  Biotech Giant Outstrips Quarterly Views, Plans New Study In Alzheimer's Investor's Business Daily
01:25PM  Biogen Inc (BIIB) Q4 2018 Earnings Conference Call Transcript Motley Fool
12:29PM  Biogen (BIIB) Q4 Earnings Beat Estimates, Revenues Up Y/Y Zacks
11:56AM  Biogen beats estimates on multiple sclerosis drugs sales Reuters
10:15AM  Dow Leads Despite Mixed Earnings Results; Apple Earnings On Deck Investor's Business Daily
10:07AM  Biogen (BIIB) Beats Revenues and Earnings Estimates in Q4 Zacks
08:56AM  Biogen Stock Running in Place Despite Strong Quarter Investopedia
07:29AM  Biogen stock up 3% after 4Q earnings beat MarketWatch
07:24AM  UPDATE 1-Biogen beats estimates on Spinraza, Tecfidera strength Reuters
06:45AM  Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar? Zacks
06:39AM  Drugmaker Biogen's fourth-quarter revenue rises 6.6 pct Reuters
01:32AM  Biogen Inc Earnings, Revenue beat in Q4
Jan-28-19 04:59PM  Biotech is breaking out. Here's what one analyst says to watch ahead of 3 key earnings reports CNBC
10:19AM  Drug/Biotech Stock Earnings on Jan 29: PFE, AMGN, BIIB & AGN Zacks
Jan-24-19 01:00PM  What's Behind the Biotech ETF Rally to Start 2019? Zacks
11:59AM  Skyrocketing health care costs key topic at Davos Yahoo Finance Video
Jan-21-19 07:35AM  The Zacks Analyst Blog Highlights: Pfizer, Biogen, Schwab, Sysco and Philips Zacks
07:15AM  Biogen (BIIB) Q4 Earnings Coming Up: What's in the Cards? Zacks
Jan-20-19 08:59AM  Which Big Pharma Stocks Lose Most in a War on Drug Price Hikes? Motley Fool
Jan-19-19 12:00PM  Better Buy: Biogen vs. Gilead Sciences Motley Fool
Jan-18-19 04:12PM  These 3 Biotech Stocks Appear Poised To Beat Fourth-Quarter Forecasts Investor's Business Daily
03:45PM  Samsung Bioepis-Merck biosimilar to Roche's Herceptin wins FDA nod Reuters
02:15PM  Top Stock Reports for Pfizer, Biogen & Schwab Zacks
Jan-17-19 10:10AM  Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report? Zacks
Jan-16-19 12:08PM  REIT Stocks, Medical Stocks Lead New Buys By The Best Mutual Funds Investor's Business Daily
Jan-14-19 04:22PM  Will Biogen Jump On This Biotech Stock Amid Buying Spree? Investor's Business Daily
Jan-10-19 04:14PM  Biogen Could Spend Nearly $18 Billion In A Takeover But Will It? Investor's Business Daily
Jan-09-19 12:29PM  Value Added: 7 Top Stocks for 2019 Kiplinger
09:33AM  Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus Zacks
Jan-08-19 02:41PM  The 10 Best Health-Care Stocks to Buy for 2019 Kiplinger
Jan-07-19 03:51PM  Biogen Inks Two Deals to Make Drugs for Neurological Diseases Zacks
Jan-06-19 07:24PM  BRIEF-Samsung Biologics JV Samsung Bioepis Partners With Chinese Biopharma 3SBio Reuters
10:00AM  All the Pre-JPM News Healthcare Investors Need to Know Motley Fool
Jan-04-19 06:13PM  Biogen Begins Improved Dosing Regimen on Tysabri in Phase III Zacks
11:18AM  Biogen doubles down on Alzheimer's with new collaboration deal American City Business Journals
07:31AM  Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets PR Newswire
07:30AM  Biogen and C4 Therapeutics Enter into Strategic Collaboration to Discover and Develop Potential New Treatments for Neurological Conditions GlobeNewswire
06:48AM  Are Biogen Inc.s (NASDAQ:BIIB) Interest Costs Too High? Simply Wall St.
Jan-03-19 07:30AM  First Patient Enrolled in Biogens Phase 3b Study to Evaluate Extended Interval Dosing (EID) with Natalizumab in Multiple Sclerosis GlobeNewswire
Jan-02-19 04:28PM  Biopharmas Restrained In Drug Pricing For 2019 With These Exceptions Investor's Business Daily
06:00AM  Top Picks 2019- Ionis Pharmaceuticals IONS MoneyShow
Dec-27-18 01:50PM  The Humira Overhang Cant Cast a Shadow on AbbVie Stock Forever InvestorPlace
09:23AM  Stocks down in December for pharma firms in the Triangle American City Business Journals
08:47AM  Perrigo Stock Up as Appeal Date for Irish Tax Bill Nears Zacks
Dec-26-18 02:22PM  6 Valuable Pipeline Drugs With Upcoming Catalysts Benzinga +5.99%
Dec-24-18 10:04AM  Perrigo Plunges on $1.9B Tax Bill From Irish Government Zacks
Dec-21-18 04:26PM  Why Gene Therapy Is More Cost Effective Than Biogen's Approved Drug Investor's Business Daily
02:52PM  AbbVie (ABBV) Seeks Approval for RA Candidate Upadacitinib Zacks
01:10PM  Perrigo Tumbles on $1.9 Billion Irish Tax Demand
12:55PM  Perrigo stock plunges toward biggest drop in 24 years after disclosing $1.9 billion Irish back-tax bill MarketWatch
Dec-20-18 09:44PM  U.S body says gene therapy may be more cost effective for spinal muscular atrophy Reuters
07:29PM  U.S body says gene therapy may be more cost effective for spinal muscular atrophy Reuters
04:13PM  6 Cheap Stocks Growing Earnings
12:19PM  Biogen Applauds Quebec Decision to Cover SPINRAZA (nusinersen) for a broad population of SMA Patients GlobeNewswire
02:52AM  [$$] Pharma Giants Plan Drug Price Hike: Report The Wall Street Journal
Dec-19-18 06:55AM  Today's Research Reports on Trending Tickers: Biogen and Biocept ACCESSWIRE
Dec-18-18 02:27PM  Biogen's Slump Is Likely to Continue -5.86%
11:55AM  Biotech Stocks Gilead Sciences and Biogen Have Room to Bounce Back
09:47AM  Alkermes, Biogen Submit NDA to FDA for Multiple Sclerosis Drug Zacks
Dec-17-18 05:29PM  Roche's SMA Candidate Risdiplam Gets PRIME Designation in EU Zacks
07:30AM  Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis GlobeNewswire
Dec-15-18 06:30AM  Better Buy: Biogen vs. Amgen Motley Fool
Dec-14-18 09:55AM  5 Incredible ETFs & Stocks to Buy on the Dip Zacks
08:23AM  5 Drug/Biotech Stocks With Promise to Sustain Bull Run in 2019 Zacks
Dec-13-18 01:40PM  Sell-Side Roundup: What's Next For For Applied Genetic After 50% Plunge? Benzinga
09:26AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis Zacks
07:56AM  The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen Benzinga
Dec-12-18 10:51AM  5 Pharma Stocks That Could Cure Ailing Portfolios in 2019 InvestorPlace
10:03AM  Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate Zacks
03:17AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen Zacks
Dec-11-18 09:00AM  4 Biotech Stocks Investors Can Add to Their Portfolio in 2019 Zacks
Dec-06-18 07:30AM  Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data GlobeNewswire
Dec-04-18 09:12AM  FDA Accepts BLA & Gives Priority Review to Novartis' AVXS-101 Zacks
Dec-03-18 09:00AM  AbbVie Presents Long-Term Data on Cancer Drugs at ASH 2018 Zacks
Nov-30-18 04:16PM  Pfizer Stock Edges Into Buy Zone On AbbVie Deal For Humira Biosimilar Investor's Business Daily
Nov-29-18 11:45AM  How To Trade Growth Stocks: Why Biogen Fell Below Its Buy Point On Breakout Day But Still Won Big Investor's Business Daily
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vounatsos MichelChief Executive OfficerFeb 12Option Exercise0.006,899016,267Feb 14 06:33 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 12Option Exercise0.004,64309,452Feb 14 06:29 PM
McKenzie PaulEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.003,06207,059Feb 14 06:17 PM
Gregory GingerEVP, Human ResourcesFeb 12Option Exercise0.001,83602,561Feb 14 06:10 PM
Ehlers Michael DEVP, Research and DevelopmentFeb 12Option Exercise0.003,82707,639Feb 14 06:07 PM
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.Feb 12Option Exercise0.003,268027,710Feb 14 06:04 PM
DENNER ALEXANDER JDirectorFeb 01Buy328.457,0002,299,163524,658Feb 01 04:19 PM
DENNER ALEXANDER JDirectorJan 31Buy330.5225,8008,527,393517,658Feb 01 04:19 PM
DENNER ALEXANDER JDirectorJan 30Buy324.8630,0009,745,851491,858Feb 01 04:19 PM
CAPELLO JEFFREY DEVP & Chief Financial OfficerJan 02Option Exercise0.001,33101,331Jan 04 04:17 PM
Guindo ChirfiEVP Glob. Mkt Acc & Cust InnovDec 01Option Exercise0.0060202,721Dec 04 08:21 PM
Ehlers Michael DEVP, Research and DevelopmentSep 26Sale350.001,000350,0004,281Sep 27 04:16 PM
Gregory GingerEVP, Human ResourcesAug 01Option Exercise0.0026201,122Aug 03 04:14 PM
Ehlers Michael DEVP, Research and DevelopmentJun 01Option Exercise0.001,38405,897Jun 05 04:31 PM
Vounatsos MichelChief Executive OfficerMay 02Option Exercise0.001,687010,118May 04 06:09 PM
DENNER ALEXANDER JDirectorApr 25Buy269.9148,00012,955,680461,858Apr 27 07:48 AM
McKenzie PaulEVP Pharmaceutical Oper & TechMar 01Option Exercise0.0053204,539Mar 05 04:41 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 27Sale290.8325975,3256,553Feb 28 05:39 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 23Option Exercise0.0046707,020Feb 27 06:25 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 23Option Exercise0.009204,772Feb 27 06:24 PM
ALEXANDER SUSAN HEVP Chief Legal Corp Svc & SecFeb 23Option Exercise0.00857025,225Feb 27 06:22 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 23Sale293.44908266,4446,553Feb 27 06:25 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 22Option Exercise0.0019404,738Feb 26 04:11 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 22Option Exercise0.001,63508,188Feb 26 04:12 PM
ALEXANDER SUSAN HEVP Chief Legal Corp Svc & SecFeb 22Option Exercise0.001,635025,095Feb 26 04:10 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 20Sale292.00743216,9566,553Feb 21 04:10 PM